4 седмици ефективно намаляване на кръвното налягане! Иновативни малки молекули, публикувани в New England Journal of Medicine

Mineralys Therapeutics recently announced that the detailed results of the critical Phase 2 clinical trial Advance HTN have been published in the New England Journal of Medicine. The experiment aims to evaluate the efficacy of the investigational therapy lorundrostat in patients with poorly controlled hypertension or refractory hypertension. The experimental results showed that lorundrostat reduced the average 24- Часов динамично систолно кръвно налягане на пациентите с 11 . 5 mmHg в сравнение с изходното ниво на 4 -та седмица; На 12 -та седмица на лечение средното 24- часова динамично систолно кръвно налягане на пациентите намалява с 13.9-15.4 mmHg, което е значително по -добро от групата на плацебо (7,4 mmHg).

Hypertension is the leading cause of cardiovascular disease and death worldwide. Although there are various antihypertensive drugs available for patients to use, less than 50% of patients can achieve blood pressure standards after medication. In about 30% of hypertensive patients, an imbalance in aldosterone level regulation is an important factor driving hypertension. Aldosterone can Популяризирайте физиологични процеси като задържане на натрий, възпаление, артериосклероза и оксидативен стрес . Следователно намаляването на синтеза на алдостерон чрез инхибиране на алдостерон синтазата е една от важните изследователски посоки за лечението на хипертонията, особено рефракторната хипертония .

Lorundrostat is an orally administered highly selective aldosterone synthase inhibitor. It reduces aldosterone levels by inhibiting the CYP11B2 enzyme responsible for aldosterone production. In vitro studies have shown that lorundrostat selectively inhibits aldosterone synthase 374 times more than cortisol synthase, and can inhibit aldosterone Синтез, без да засяга нивата на кортизол . При хипертонични лица, плазмената концентрация на алдостерон може да бъде намалена с около 70%.

The Advance HTN trial is a randomized, double-blind, placebo-controlled phase 2 clinical study evaluating the efficacy and safety of lorundrostat as an adjunct therapy to two or three standard antihypertensive drug background treatments in adult patients with poorly controlled or refractory hypertension. In terms of secondary endpoints, compared to placebo, the lorundrostat group showed superior blood pressure lowering effects На 4 -та седмица на лечението: Групата Lorundrostat имаше средно понижение на систолното кръвно налягане от 11 . 5 mmHg, докато плацебо групата има стойност 6,2 mmHg.

In March of this year, Mineralys announced that lorundrostat had also reached its primary endpoint in another critical phase 3 clinical trial, Launch HTN. The company plans to further disclose data from the Launch HTN trial at the upcoming medical conference. In addition, the ongoing Transformer HTN open label extension trial allows participants to continue receiving lorundrostat treatment to obtain more safety and efficacy Данни .